[A19-14] Palbociclib (breast cancer) - Addendum to Commission A18-63
Last updated 22.03.2019
Project no.:
A19-14
Commission:
Commission awarded on 11.03.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Women with HR-positive, HER2-negative advanced or metastatic breast cancer with progression after endocrine therapy
Added benefit still not proven after analysis of further data from the PALOMA-3 study
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-63 | Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.